We have located links that may give you full text access.
COMPARATIVE STUDY
JOURNAL ARTICLE
RANDOMIZED CONTROLLED TRIAL
Combined oral contraceptives in women with menstrual migraine without aura.
Fertility and Sterility 2011 October
OBJECTIVE: To compare the efficacy of two regimens (21 active pills + 7 placebo pills vs. 24 active pills + 4 placebo pills) of combined oral contraception (COC), both containing 20 μg of ethinyl E(2) and 3 mg of drospirenone, in improving the severity of pure menstrual migraine without aura.
DESIGN: Prospective randomized study.
SETTING: Patients attending the gynecology department of the University of Siena for consultation regarding an appropriate contraception.
PATIENT(S): Women ages 20 to 35 years (n = 60) suffering from pure menstrual migraine without aura.
INTERVENTION(S): Three months of contraceptive use (ethinyl E(2) 20 μg/drospirenone 3 mg) in two different regimens: group A received 21 active + 7 placebo pills whereas group B received 24 active + 4 placebo pills.
MAIN OUTCOME MEASURE(S): Monthly evaluation of the duration and severity of patients' daily headache attacks.
RESULT(S): Although both study groups demonstrated significant reduction in the intensity and duration of menstrual migraine, patients in group B (24/4 COC) reported a significant reduction in the intensity and a shorter duration of their menstrual migraine, compared with group A (21/7 COC).
CONCLUSION(S): The 24/4 COC regimen is recommended as the preferred treatment for patients suffering from pure menstrual migraine without aura.
DESIGN: Prospective randomized study.
SETTING: Patients attending the gynecology department of the University of Siena for consultation regarding an appropriate contraception.
PATIENT(S): Women ages 20 to 35 years (n = 60) suffering from pure menstrual migraine without aura.
INTERVENTION(S): Three months of contraceptive use (ethinyl E(2) 20 μg/drospirenone 3 mg) in two different regimens: group A received 21 active + 7 placebo pills whereas group B received 24 active + 4 placebo pills.
MAIN OUTCOME MEASURE(S): Monthly evaluation of the duration and severity of patients' daily headache attacks.
RESULT(S): Although both study groups demonstrated significant reduction in the intensity and duration of menstrual migraine, patients in group B (24/4 COC) reported a significant reduction in the intensity and a shorter duration of their menstrual migraine, compared with group A (21/7 COC).
CONCLUSION(S): The 24/4 COC regimen is recommended as the preferred treatment for patients suffering from pure menstrual migraine without aura.
Full text links
Related Resources
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app
All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.
By using this service, you agree to our terms of use and privacy policy.
Your Privacy Choices
You can now claim free CME credits for this literature searchClaim now
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app